Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Inquiry Memorial
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Support and FAQs
    • NHS Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Hepatitis C Testing
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

Dr Craske wrote to the Small Grants Secretariat recording that whilst haemophilia centre directors had agreed in theory to maintaining patients on single batches or brands, the shortage of Factor VIII, large numbers of patients under treatment and the cost of maintaining stocks of Factor VIII meant that they did not consider it to be a practical policy to stick rigidly to this regime.

Published on: 27 September, 2024

Dr Mary Collins on behalf of the DHSS said regarding self-sufficiency that there was no limit on the amount of commercial material which Haemophilia Centres could receive.

Published on: 27 September, 2024

In a meeting of the haemophilia centre directors, it was reported that the 1976 and 1977 annual returns from haemophilia centres demonstrated that an increasingly large amount of commercial Factor 8 concentrate was being used by centres.

Published on: 27 September, 2024

The Hepatitis Working Party agreed to continue the study on the Oxford Haemophiliacs to obtain more evidence of the relationship of transaminitis and overt chronic liver disease to mortality.

Published on: 27 September, 2024

There was little discussion of issues relating to hepatitis at the haemophilia reference centre directors'

Published on: 27 September, 2024

Dr Craske gave a presentation on the work of the Hepatitis Working Party at the UKHCDO annual meeting

Published on: 27 September, 2024

The Hepatitis Working Party agreed more information was needed on the risk to patients of developing chronic NANBH, by prospectively following patients first exposed to concentrate or other products, such as people with mild haemophilia undergoing non-emergency surgery.

Published on: 27 September, 2024

Dr Peter Jones became director of the Newcastle Haemophilia Centre.

Published on: 27 September, 2024

Dr Peter Jones believed the major part of his responsibility was "a regional commitment to the care of children and adults with haemophilia".

Published on: 27 September, 2024

There were 43 patients on home therapy, with a mean Factor 8 usage of 18,796 units per patient per year at Newcastle Haemophilia Centre.

Published on: 27 September, 2024

Prophylaxis was a feature of treatment policy at Newcastle Haemophilia Centre.

Published on: 27 September, 2024

Dr Peter Jones had no doubt that haemophiliacs exposed to multi donor concentrates were infected with non-A non-B hepatitis and that a substantial number would go on to develop chronic liver disease.

Published on: 27 September, 2024

Dr Peter Jones suggested AIDS in haemophilia patients was brought to the attention of haemophilia centre directors by Professor Bloom at a meeting of the Haemophilia Reference Centre Directors.

Published on: 27 September, 2024

Dr Peter Jones was joined by Dr Peter Hamilton as co-director of the Newcastle Haemophilia Centre.

Published on: 27 September, 2024

Dr Jones' "Guidelines for the Organisation of a Haemophilia Centre" recorded that "within our geographical region, which has a population of 3.3 million, the home therapy programme is run from the Newcastle Centre and all patients are followed up there by the core team."

Published on: 27 September, 2024

In a letter from Dr Jones to Dr Sackwood, it was noted that 23 patients were on home therapy in the Newcastle area.

Published on: 27 September, 2024

Dr Jones suggested in his statement to the Inquiry, that cryoprecipitate was the treatment of choice until 1973, "when sufficient Factor VIII became available".

Published on: 09 October, 2024

Dr Jones stated that the introduction of concentrates allowed the development of home therapy and eventually prophylactic treatment.

Published on: 27 September, 2024

Dr Jones suggested that the Newcastle centre's policy was to encourage both home and prophylaxis treatment.

Published on: 27 September, 2024

Dr Jones told his patients that a substantial proportion of those infected with NANBH would develop liver disease

Published on: 27 September, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2104
  • Page 2105
  • Page 2106
  • Page 2107
  • Current page 2108
  • Page 2109
  • Page 2110
  • Page 2111
  • Page 2112
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.